OR WAIT null SECS
September 16, 2021
Deal is dependent on FDA approval of Phathom’s vonoprazan compound
September 15, 2021
Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot
September 14, 2021
Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions
September 13, 2021
Latest construction plan continues CDMO’s vision for biopharma expansion
September 09, 2021
CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand
September 08, 2021
After previously going bankrupt, center is now under US ownership for the first time
September 02, 2021
Swiss organization will take patient-centric approach towards developing injectables
September 01, 2021
Company’s prospective malaria and tuberculosis doses will be developed in Rwanda, Senegal
Irvine, CA, location will house 40,000 square feet of oral solid dosage forms
August 25, 2021
Swiss CDMO’s expansion at recently opened Guangzhou plant expected to be ready by next year
